Marc Bellalta-Corbera

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications

The IL-6 axis in vascular inflammation: effects of IL-6 receptor blockade on vascular lesions from patients with giant-cell arteritis.

The IL-6 axis in vascular inflammation: effects of IL-6 receptor blockade on vascular lesions from patients with giant-cell arteritis.

Journal: Annals of the rheumatic diseases
Published: February 06, 2025

Biopsy vs imaging for the diagnosis of giant cell arteritis. Viewpoint 2: in favour of biopsy.

Biopsy vs imaging for the diagnosis of giant cell arteritis. Viewpoint 2: in favour of biopsy.

Journal: Rheumatology (Oxford, England)
Published: July 26, 2024

Current evidence on the role of fibroblasts in large-vessel vasculitides: From pathogenesis to therapeutics.

Current evidence on the role of fibroblasts in large-vessel vasculitides: From pathogenesis to therapeutics.

Journal: Autoimmunity reviews
Published: March 11, 2024

miR-146a and miR-146b regulate the expression of ICAM-1 in giant cell arteritis.

miR-146a and miR-146b regulate the expression of ICAM-1 in giant cell arteritis.

Journal: Journal of autoimmunity
Published: September 30, 2023

Neointimal myofibroblasts contribute to maintaining Th1/Tc1 and Th17/Tc17 inflammation in giant cell arteritis.

Neointimal myofibroblasts contribute to maintaining Th1/Tc1 and Th17/Tc17 inflammation in giant cell arteritis.

Journal: Journal of autoimmunity
Published: August 31, 2023

Human monocyte-derived suppressive cells (HuMoSC) for cell therapy in giant cell arteritis.

Human monocyte-derived suppressive cells (HuMoSC) for cell therapy in giant cell arteritis.

Journal: Frontiers in immunology
Published: January 04, 2023

Blocking GM-CSF receptor α with mavrilimumab reduces infiltrating cells, pro-inflammatory markers and neoangiogenesis in ex vivo cultured arteries from patients with giant cell arteritis.

Blocking GM-CSF receptor α with mavrilimumab reduces infiltrating cells, pro-inflammatory markers and neoangiogenesis in ex vivo cultured arteries from patients with giant cell arteritis.

Journal: Annals of the rheumatic diseases
Published: May 27, 2021

Improvement of Treg immune response after treatment with tocilizumab in giant cell arteritis.

Improvement of Treg immune response after treatment with tocilizumab in giant cell arteritis.

Journal: Clinical & translational immunology
Published: January 25, 2021

PI3Kδ inhibition reshapes follicular lymphoma-immune microenvironment cross talk and unleashes the activity of venetoclax.

PI3Kδ inhibition reshapes follicular lymphoma-immune microenvironment cross talk and unleashes the activity of venetoclax.

Journal: Blood advances
Published: February 02, 2020

Expression and Function of IL12/23 Related Cytokine Subunits (p35, p40, and p19) in Giant-Cell Arteritis Lesions: Contribution of p40 to Th1- and Th17-Mediated Inflammatory Pathways.

Expression and Function of IL12/23 Related Cytokine Subunits (p35, p40, and p19) in Giant-Cell Arteritis Lesions: Contribution of p40 to Th1- and Th17-Mediated Inflammatory Pathways.

Journal: Frontiers in immunology
Published: December 14, 2017

Biological treatments in giant cell arteritis & Takayasu arteritis.

Biological treatments in giant cell arteritis & Takayasu arteritis.

Journal: European journal of internal medicine
Published: October 24, 2017

Serum osteopontin: a biomarker of disease activity and predictor of relapsing course in patients with giant cell arteritis. Potential clinical usefulness in tocilizumab-treated patients.

Serum osteopontin: a biomarker of disease activity and predictor of relapsing course in patients with giant cell arteritis. Potential clinical usefulness in tocilizumab-treated patients.

Journal: RMD open
Published: September 04, 2017
Showing 1-12 of 21

Last Updated: 09/26/2026